-
-
-
-
-
-
-
Baird Maintains Neutral Ratings and $3 PT on Proteon Therapeutics (PRTO); 'Encouraging Amendments to PATENCY-2 Trial Design'
-
-
-
-
-
-
-
Baird Starts Proteon Therapeutics (PRTO) at Outperform
-
-
27,186 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

